Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era out on JAMA internal Medicine jamanetwork.com/journals/jamai… This cohort study examined overtreatment trends for men with limited life expectancy (LE) and clinically localized

Germline and Somatic Genomic Testing for Metastatic #ProstateCancer : ASCO Guideline ascopubs.org/doi/10.1200/JC… A systematic review was conducted by a multidisciplinary panel, analyzing literature from January 2018 to May 2024, with 14 studies meeting the inclusion criteria.

Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone out on European Urology sciencedirect.com/science/articl… Bone health is a crucial aspect of managing metastatic

#GU25 highlights #CommunityOnc: 1. Radical ✂️ vs. XRT high risk PCa 2. #TALAPRO2: PARPi in M1 CRPC 3. #EnzaP: ARPi + LuPSMA in M1 CRPC 4. #NIAGARA update: Resectable MIBC 5. #EV302 update: Metastatic #BladderCancer 6. #CM9ER update: 1L mRCC #OncTwitter #gism ASCO 1/7

ENZA-p trial update: Adding Lu-PSMA-617 to enzalutamide improved OS (34 vs 26 mo, HR 0.55) & delayed QoL deterioration in mCRPC. A strong case for phase 3 trials! #GU25 #cancer #oncology @asco @oncoalert The Lancet Oncology Michael Hofman Ian Davis (Bluesky @profiand) Louise Emmett

Real-world treatment patterns in advanced #ProstateCancer from #PRECISION data platform. Oliver Sartor, MD Mayo Clinic sits down with Zach Klaassen Georgia Cancer Center, highlighting the registry's value in providing real-world snapshots of evolving treatment patterns in the

🚀Paradigm Shift in Oligometastatic Prostate Cancer? SBRT + ADT Doubles Progression-Free Survival! OncoAlert 🎯 Objective Does adding 6 months of ADT to SBRT ⬆️clinical progression-free survival (cPFS) vs. SBRT alone? 🏥 Methods •Ph2, randomized trial (105 👥, Milan, Italy)

Exciting progress in the management of de novo #mHSPC ! A new consensus from the Italian Association of Radiotherapy and Clinical Oncology #AIRO highlights the growing role of radiotherapy alongside emerging therapies, showing survival benefits & improved outcomes. Key insights

🚨SBRT+ADT for oligometastatic #prostatecancer 👉RADIOSA trial The Lancet Oncology 💉6 months of ADT prolonged time to clinical progression from 15 to 32 months 🔗shorturl.at/0p062

Patient-level data confirms ARPI value in #mHSPC treatment in meta-analysis. David Fisher, MA, MSc MRC Clinical Trials Unit at UCL joins Neeraj Agarwal, MD, FASCO Huntsman Cancer Institute in this discussion. Key finding reveals that efficacy decreases by approximately 15% for each decade older, with patients over 75 showing

Data from Peace3 presented by Fred Saad clearly suggest that early administration of bone protecting agent increase rPFS and OS in patients receiving enzalutamide +- Ra223 EORTC GETUG SOGUG LACOG - Latin American Cooperative Oncology Group silke gillessen #EAU2025

High-risk biochemical recurrence with positive PSMA PET: Radiotherapy still matters. Presentation by Valérie Fonteyne UZ Gent. #EAU25 written coverage by Rashid K. Sayyid USC > bit.ly/4l33Sy7 European Association of Urology (EAU)

State-of-the-Art Lecture – Screening in #RCC: How, When, Who? Presentation by Teele Kuusk, MD Cambridge University Hospitals NHS. #EAU25 written coverage by Rashid K. Sayyid USC > bit.ly/4iZeEUg European Association of Urology (EAU)

Treatment Algorithm: This is the algorithm we’ve used during our discussion w/ Alan H Bryce on #ProstateCancer. #OncTwitter #MedTwitter CancerNetwork®

Costos en USD de los tratamientos para las distintas etapas del #cáncer de vejiga: no músculo invasor/ músculo invasor / enfermedad metastásica #EAU25 #EAU2025 #cancerdevejiga #bladdercancer

Novel hormonal agents in men with #mCRPC and reduced performance status: Experiences of a specialized single center. #mCRPC in frail patients (ECOG ≥2) challenges NHA benefits. A single-center study found no OS advantage with enzalutamide/abiraterone vs. best supportive care.

The proteogenomics of #ProstateCancer radioresistance. Roni Haas UCLA joins Andrea Miyahira Prostate Cancer Foundation to discuss research on prostate cancer radioresistance, focusing on differences between conventional and hypofractionated radiation therapy approaches. #FullVideo on UroToday >

Still too much ADT alone… In this VA study of 6216 veterans with de novo mHSPC: 📅 2022... and still 37% got only ADT! 🔵Combo therapy = longer OS (40.3 vs 33.0 mo) 🔵Not only biology, also delivery does matter! JAMA Network Open OncoAlert Advanced Prostate Cancer Consensus Conference Prostate Cancer Foundation

🧾 New Cheat Sheet on Prostate Cancer Treatment by Stage 🔹 Low-risk: Active surveillance; avoid ADT 🔹 Intermediate-risk: Surgery or RT; ADT case-based 🔹 High-risk: Surgery/RT + long-term ADT #EAUguidelines #ProstateCancer Download Cheat Sheet here: uroweb.org/guidelines/pro…

42 YO obese male w/ multiple renal stones. ECIRS made the trick. Great surgery, great team, stone free at last !!!! #ECIRS, Fábio Sepúlveda endourology Nitesh Kumar Edgar Iván Bravo 🇲🇽😬🤘🏻 Saeed Bin Hamri Urology Times Kemal Sarıca Endourology Academy